Q3 EPS Estimate for Crescent Biopharma Reduced by Analyst

Posted by Brian Himes on Aug 5th, 2026

Crescent Biopharma, Inc. (NASDAQ:CBIO – Free Report) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Crescent Biopharma in a report issued on Friday, July 31st. HC Wainwright analyst M. Kapoor now anticipates that the biopharmaceutical company will earn ($0.85) per share for the quarter, down from their previous estimate of ($0.80). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Crescent Biopharma’s current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Crescent Biopharma’s Q4 2026 earnings at ($0.86) EPS, FY2026 earnings at ($3.30) EPS, Q2 2027 earnings at ($1.08) EPS, Q3 2027 earnings at ($1.16) EPS, Q4 2027 earnings at ($1.37) EPS and FY2027 earnings at ($4.60) EPS.

Crescent Biopharma (NASDAQ:CBIO – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) EPS for the quarter, meeting the consensus estimate of ($0.74).

Separately, Weiss Ratings upgraded shares of Crescent Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.40.

View Our Latest Stock Analysis on CBIO

Crescent Biopharma Stock Performance

Crescent Biopharma stock opened at $16.38 on Wednesday. The stock has a fifty day moving average of $17.18 and a 200-day moving average of $15.89. The stock has a market capitalization of $451.43 million, a P/E ratio of -2.44 and a beta of 1.23. Crescent Biopharma has a 52 week low of $8.72 and a 52 week high of $27.41.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Fcpm Iii Services B.V. bought a new position in Crescent Biopharma in the 4th quarter valued at approximately $19,899,000. Vestal Point Capital LP acquired a new stake in Crescent Biopharma during the 4th quarter worth approximately $17,790,000. BVF Inc. IL grew its holdings in Crescent Biopharma by 98.1% during the 4th quarter. BVF Inc. IL now owns 2,748,763 shares of the biopharmaceutical company’s stock worth $32,600,000 after acquiring an additional 1,360,900 shares during the last quarter. Opaleye Management Inc. bought a new stake in Crescent Biopharma during the 4th quarter worth approximately $13,975,000. Finally, Vanguard Group Inc. acquired a new position in Crescent Biopharma in the 3rd quarter valued at approximately $7,822,000. Institutional investors and hedge funds own 75.19% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Joshua T. Brumm sold 42,305 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $17.99, for a total transaction of $761,066.95. Following the sale, the chief executive officer owned 281,212 shares in the company, valued at $5,059,003.88. The trade was a 13.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jonathan Mcneill sold 20,549 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $17.99, for a total value of $369,676.51. Following the completion of the transaction, the chief operating officer directly owned 139,158 shares of the company’s stock, valued at approximately $2,503,452.42. The trade was a 12.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 68,156 shares of company stock worth $1,226,126 in the last 90 days. 24.84% of the stock is currently owned by corporate insiders.

Crescent Biopharma Company Profile

(Get Free Report)

Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.